Respiratory Syncytial Virus Modified by Deletions of the NS2 Gene and Amino Acid S1313 of the L Polymerase Protein Is a Temperature- Sensitive, Live-Attenuated Vaccine Candidate That Is Phenotypically Stable at Physiological Temperature

Journal of Virology

Volumn 87, Issue 4, 2013, Pages 1985-1996

  Luongo, Cindy ^a   Winter, Christine C ^a   Collins, Peter L ^a   Buchholz, Ursula J ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOLEUCINE; L POLYMERASE; LEUCINE; LIVE VACCINE; MEDI 559; RECOMBINANT VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; SERINE; THREONINE; UNCLASSIFIED DRUG; VIRUS ENZYME; VIRUS VACCINE;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHIMPANZEE; CONTROLLED STUDY; FEMALE; GENE DELETION; GENETIC STABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LOWER RESPIRATORY TRACT; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; NS2 GENE; PHENOTYPE; PNEUMOVIRUS INFECTION; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; TEMPERATURE SENSITIVITY; UPPER RESPIRATORY TRACT; VIRUS GENE; VIRUS REPLICATION;

ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; GENE DELETION; HUMANS; MICE; MICE, INBRED BALB C; MUTATION, MISSENSE; PAN TROGLODYTES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; RESPIRATORY TRACT INFECTIONS; TEMPERATURE; VACCINES, ATTENUATED; VIRAL PROTEINS; VIRULENCE;

EID: 84873744697     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02769-12     Document Type: Article

References (38)

1. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O'Brien KL, Roca A, Wright PF, Bruce N, Chandran A, Theodoratou E, Sutanto A, Sedyaningsih ER, Ngama M, Munywoki PK, Kartasasmita C, Simoes EA, Rudan I, Weber MW, Campbell H. 2010. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375:1545-1555.
2. Canfield SD, Simoes EA. 1999. Prevention of respiratory syncytial virus (RSV) infection: RSV immune globulin intravenous and palivizumab. (American Academy of Pediatrics). Pediatr. Ann. 28:507-514.
3. Collins PL, Melero JA. 2011. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res. 162: 80-99.
4. Collins PL, Murphy BR. 2005. New generation live vaccines against human respiratory syncytial virus designed by reverse genetics. Proc. Am. Thorac. Soc. 2:166-173.
5. Schmidt AC. 2011. Progress in respiratory virus vaccine development. Semin. Respir. Crit. Care Med. 32:527-540.
6. Wright PF, Belshe RB, Kim HW, Van Voris LP, Chanock RM. 1982. Administration of a highly attenuated, live respiratory syncytial virus vaccine to adults and children. Infect. Immun. 37:397-400.
7. Wright PF, Karron RA, Belshe RB, Thompson J, Crowe JE, Jr, Boyce TG, Halburnt LL, Reed GW, Whitehead SS, Anderson EL, Wittek AE, Casey R, Eichelberger M, Thumar B, Randolph VB, Udem SA, Chanock RM, Murphy BR. 2000. Evaluation of a live, cold-passaged, temperaturesensitive, respiratory syncytial virus vaccine candidate in infancy. J. Infect. Dis. 182:1331-1342.
8. Wright PF, Shinozaki T, Fleet W, Sell SH, Thompson J, Karzon DT. 1976. Evaluation of a live, attenuated respiratory syncytial virus vaccine in infants. J. Pediatr. 88:931-936.
9. Karron RA, Wright PF, Belshe RB, Thumar B, Casey R, Newman F, Polack FP, Randolph VB, Deatly A, Hackell J, Gruber W, Murphy BR, Collins PL. 2005. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J. Infect. Dis. 191:1093-1104.
10. Lin YH, Deatly AM, Chen W, Miller LZ, Lerch R, Sidhu MS, Udem SA, Randolph VB. 2006. Genetic stability determinants of temperature sensitive, live attenuated respiratory syncytial virus vaccine candidates. Virus Res. 115:9-15.
11. Luongo C, Winter CC, Collins PL, Buchholz UJ. 2012. Increased genetic and phenotypic stability of a promising live-attenuated respiratory syncytial virus vaccine candidate by reverse genetics. J. Virol. 86:10792-10804.
12. Luongo C, Yang L, Winter CC, Spann KM, Murphy BR, Collins PL, Buchholz UJ. 2009. Codon stabilization analysis of the "248" temperature sensitive mutation for increased phenotypic stability of respiratory syncytial virus vaccine candidates. Vaccine 27:5667-5676.
13. Jin H, Zhou H, Cheng X, Tang R, Munoz M, Nguyen N. 2000. Recombinant respiratory syncytial viruses with deletions in the NS1, NS2, SH, and M2-2 genes are attenuated in vitro and in vivo. Virology 273:210-218.
14. Teng MN, Collins PL. 1999. Altered growth characteristics of recombinant respiratory syncytial viruses which do not produce NS2 protein. J. Virol. 73:466-473.
15. Buchholz UJ, Finke S, Conzelmann KK. 1999. Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. J. Virol. 73:251-259.
16. Spann KM, Tran KC, Chi B, Rabin RL, Collins PL. 2004. Suppression of the induction of alpha, beta, and lambda interferons by the NS1 and NS2 proteins of human respiratory syncytial virus in human epithelial cells and macrophages [corrected]. J. Virol. 78:4363-4369.
17. Mosca JD, Pitha PM. 1986. Transcriptional and posttranscriptional regulation of exogenous human beta interferon gene in simian cells defective in interferon synthesis. Mol. Cell. Biol. 6:2279-2283.
18. Murphy BR, Sotnikov AV, Lawrence LA, Banks SM, Prince GA. 1990. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization. Vaccine 8:497-502.
19. Crowe JE, Jr, Collins PL, London WT, Chanock RM, Murphy BR. 1993. A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV. Vaccine 11:1395-1404.
20. Collins PL, Hill MG, Camargo E, Grosfeld H, Chanock RM, Murphy BR. 1995. Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5= proximal open reading frame of theM2mRNAin gene expression and provides a capability for vaccine development. Proc. Natl. Acad. Sci. U. S. A. 92:11563-11567.
21. Bukreyev A, Belyakov IM, Berzofsky JA, Murphy BR, Collins PL. 2001. Granulocyte-macrophage colony-stimulating factor expressed by recombinant respiratory syncytial virus attenuates viral replication and increases the level of pulmonary antigen-presenting cells. J. Virol. 75:12128-12140.
22. Witko SE, Kotash CS, Nowak RM, Johnson JE, Boutilier LA, Melville KJ, Heron SG, Clarke DK, Abramovitz AS, Hendry RM, Sidhu MS, Udem SA, Parks CL. 2006. An efficient helper-virus-free method for rescue of recombinant paramyxoviruses and rhadoviruses from a cell line suitable for vaccine development. J. Virol. Methods 135:91-101.
23. Whitehead SS, Firestone CY, Collins PL, Murphy BR. 1998. A single nucleotide substitution in the transcription start signal of the M2 gene of respiratory syncytial virus vaccine candidate cpts248/404 is the major determinant of the temperature-sensitive and attenuation phenotypes. Virology 247:232-239.
24. Erwin J, Landon JC. 1992. Spacious biocontainment suites for chimpanzees in infectious disease research, p 65-69. In Erwin J, Landon JC (ed), Chimpanzee conservation and public health: environments for the future. Diagnon/Bioqual, Rockville, MD.
25. Friedewald WT, Forsyth BR, Smith CB, Gharpure MA, Chanock RM. 1968. Low-temperature-grown RS virus in adult volunteers. JAMA 204: 690-694.
26. Whitehead SS, Juhasz K, Firestone CY, Collins PL, Murphy BR. 1998. Recombinant respiratory syncytial virus (RSV) bearing a set of mutations from cold-passaged RSV is attenuated in chimpanzees. J. Virol. 72:4467-4471.
27. Bukreyev A, Whitehead SS, Murphy BR, Collins PL. 1997. Recombinant respiratory syncytial virus from which the entire SH gene has been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse. J. Virol. 71:8973-8982.
28. Whitehead SS, Bukreyev A, Teng MN, Firestone CY, St Claire M, Elkins WR, Collins PL, Murphy BR. 1999. Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees. J. Virol. 73:3438-3442.
29. Crowe JE, Jr, Bui PT, London WT, Davis AR, Hung PP, Chanock RM, Murphy BR. 1994. Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis. Vaccine 12:691-699.
30. Teng MN, Whitehead SS, Bermingham A, St Claire M, Elkins WR, Murphy BR, Collins PL. 2000. Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees. J. Virol. 74:9317-9321.
31. Simitsek PD, Campbell DG, Lanzavecchia A, Fairweather N, Watts C. 1995. Modulation of antigen processing by bound antibodies can boost or suppress class II major histocompatibility complex presentation of different T cell determinants. J. Exp. Med. 181:1957-1963.
32. Watts C, Lanzavecchia A. 1993. Suppressive effect of antibody on processing of T cell epitopes. J. Exp. Med. 178:1459-1463.
33. Bartlett EJ, Castano A, Surman SR, Collins PL, Skiadopoulos MH, Murphy BR. 2007. Attenuation and efficacy of human parainfluenza virus type 1 (HPIV1) vaccine candidates containing stabilized mutations in the P/C and L genes. Virol. J. 4:67.
34. Nolan SM, Skiadopoulos MH, Bradley K, Kim OS, Bier S, Amaro- Carambot E, Surman SR, Davis S, St Claire M, Elkins R, Collins PL, Murphy BR, Schaap-Nutt A. 2007. Recombinant human parainfluenza virus type 2 vaccine candidates containing a 3= genomic promoter mutation and L polymerase mutations are attenuated and protective in nonhuman primates. Vaccine 25:6409-6422.
35. Karron RA, Wright PF, Crowe JE, Jr, Clements-Mann ML, Thompson J, Makhene M, Casey R, Murphy BR. 1997. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. J. Infect. Dis. 176:1428-1436.
36. Valarcher JF, Furze J, Wyld S, Cook R, Conzelmann KK, Taylor G. 2003. Role of alpha/beta interferons in the attenuation and immunogenicity of recombinant bovine respiratory syncytial viruses lacking NS proteins. J. Virol. 77:8426-8439.
37. Crowe JE, Jr, Bui PT, Davis AR, Chanock RM, Murphy BR. 1994. A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees. Vaccine 12:783-790.
38. Coates HV, Alling DW, Chanock RM. 1966. An antigenic analysis of respiratory syncytial virus isolates by a plaque reduction neutralization test. Am. J. Epidemiol. 83:299-313.